Starling Oncology, Inc. (STLN) stock
STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
$3.50−0.25 (-6.67%)
Close on Nov 13, 2026Market cap $356.71MP/E –Yield –
Starling Oncology enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Starling Oncology's enterprise value was $460.74M on Nov 11, 2026, against $354.91M a year earlier. Over the last 5 years it ranged from $44.18M to $694.84M, with a median of $212.72M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $460.74M | +16.4% |
| 2025 | Dec 31, 2025 | $395.89M | +486.6% |
| 2024 | Dec 31, 2024 | $67.48M | -54.5% |
| 2023 | Dec 29, 2023 | $148.25M | +37.5% |
| 2022 | Dec 30, 2022 | $107.85M | -49.3% |
| 2021 | Dec 31, 2021 | $212.72M | +248.1% |
| 2020 | Dec 31, 2020 | $61.10M | – |
See a number that looks wrong?